Ovarian Cancer | Specialty

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

January 14th 2021

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Dr. Konecny on the Survival Benefit Achieved With Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Dr. Zakhour on Clinical Trials Examining Frontline Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Mae Zakhour, MD, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.

Dr. Naumann on the TOPACIO Trial With Pembrolizumab/Niraparib in Ovarian Cancer

January 12th 2021

R. Wendel Naumann, MD, discusses the significance of the phase 1/2 TOPACIO trial in ovarian cancer.

Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian Cancer

January 11th 2021

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Dr. Crane on the Benefit of Maintenance PARP Inhibitors in Ovarian Cancer

January 8th 2021

Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.

Dr. Brown on the Utility of Minimally Invasive Surgery in Ovarian Cancer

January 8th 2021

Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.

RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer

January 6th 2021

January 6, 2021 — The oral small molecule inhibitor VS-6766, developed by Verastem Oncology, is now under investigation alone and in combination with the FAK inhibitor defactinib in a recently initiated, registration-directed, phase 2 trial in patients with recurrent low-grade serous ovarian cancer.

x